QVAR? Gets More Medicine Where It Needs to Go3
* QVAR is the first and only small particle ICS indicated for patients as young as 5 years of age6
* QVAR outdistances fluticasone in improving lung function4
* QVAR delivers up to 58% lung deposition*5,10
* QVAR is a prodrug. That means the inactive drug deposited in the mouth and oropharynx is swallowed before activation can occur. As a result, QVAR is associated with a very low incidence of oropharyngeal side effects8,9
* QVAR?s extra-fine particles, just 1.1 microns1 treat inflammation in even the smallest airways where more than half of asthma-related airway resistance takes place2
* QVAR can be used with or without a spacer6
QVAR: a small-particle ICS, designed to reach inflammation in even the smallest airways
QVAR? is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age or older. QVAR is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR may reduce or eliminate the need for systemic corticosteroids.
Important Safety Information
* QVAR is not a bronchodilator and is not indicated for relief of acute bronchospasm
* Common side effects associated with the use of QVAR and placebo in clinical trials include, but are not limited to, headache (12% and 9%,
respectively) and pharyngitis (8% and 4%, respectively)
CAUTION: Adrenal insufficiency may occur when transferring patients from systemic steroids (see WARNINGS, Prescribing Information)
* A reduction in growth velocity in growing children and teenagers may occur as a result of inadequate control of chronic diseases such as
asthma or from use of corticosteroids for treatment
